231 related articles for article (PubMed ID: 22042973)
1. Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment.
Yang J; Ylipää A; Sun Y; Zheng H; Chen K; Nykter M; Trent J; Ratner N; Lev DC; Zhang W
Clin Cancer Res; 2011 Dec; 17(24):7563-73. PubMed ID: 22042973
[TBL] [Abstract][Full Text] [Related]
2. Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor.
Du X; Yang J; Ylipää A; Zhu Z
J Hematol Oncol; 2013 Dec; 6():93. PubMed ID: 24341609
[TBL] [Abstract][Full Text] [Related]
3. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
Zou CY; Smith KD; Zhu QS; Liu J; McCutcheon IE; Slopis JM; Meric-Bernstam F; Peng Z; Bornmann WG; Mills GB; Lazar AJ; Pollock RE; Lev D
Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153
[TBL] [Abstract][Full Text] [Related]
4. Prognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumor.
Zhou W; Du X; Song F; Zheng H; Chen K; Zhang W; Yang J
Oncotarget; 2016 Apr; 7(16):22234-44. PubMed ID: 26993773
[TBL] [Abstract][Full Text] [Related]
5. IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias.
Gusscott S; Jenkins CE; Lam SH; Giambra V; Pollak M; Weng AP
PLoS One; 2016; 11(8):e0161158. PubMed ID: 27532210
[TBL] [Abstract][Full Text] [Related]
6. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
[TBL] [Abstract][Full Text] [Related]
8. Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor.
Yu J; Deshmukh H; Payton JE; Dunham C; Scheithauer BW; Tihan T; Prayson RA; Guha A; Bridge JA; Ferner RE; Lindberg GM; Gutmann RJ; Emnett RJ; Salavaggione L; Gutmann DH; Nagarajan R; Watson MA; Perry A
Clin Cancer Res; 2011 Apr; 17(7):1924-34. PubMed ID: 21325289
[TBL] [Abstract][Full Text] [Related]
9. Genomic and molecular aberrations in malignant peripheral nerve sheath tumor and their roles in personalized target therapy.
Yang J; Du X
Surg Oncol; 2013 Sep; 22(3):e53-7. PubMed ID: 23830351
[TBL] [Abstract][Full Text] [Related]
10. Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors.
Ahsan S; Ge Y; Tainsky MA
Oncotarget; 2016 Aug; 7(35):57171-57185. PubMed ID: 27494873
[TBL] [Abstract][Full Text] [Related]
11. BL1391: an established cell line from a human malignant peripheral nerve sheath tumor with unique genomic features.
Tolomeo D; Agostini A; Macchia G; L'Abbate A; Severgnini M; Cifola I; Frassanito MA; Racanelli V; Solimando AG; Haglund F; Mertens F; Storlazzi CT
Hum Cell; 2021 Jan; 34(1):238-245. PubMed ID: 32856169
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
Ambrosini G; Cheema HS; Seelman S; Teed A; Sambol EB; Singer S; Schwartz GK
Mol Cancer Ther; 2008 Apr; 7(4):890-6. PubMed ID: 18413802
[TBL] [Abstract][Full Text] [Related]
13. Decorin suppresses stemness and migration potential of malignant peripheral nerve sheath tumor through inhibiting epidermal growth factor receptor signaling.
Jia X; Chen L; Yu C
Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167181. PubMed ID: 38653361
[TBL] [Abstract][Full Text] [Related]
14. Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.
Patel AV; Eaves D; Jessen WJ; Rizvi TA; Ecsedy JA; Qian MG; Aronow BJ; Perentesis JP; Serra E; Cripe TP; Miller SJ; Ratner N
Clin Cancer Res; 2012 Sep; 18(18):5020-30. PubMed ID: 22811580
[TBL] [Abstract][Full Text] [Related]
15. Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.
Jameson MJ; Beckler AD; Taniguchi LE; Allak A; Vanwagner LB; Lee NG; Thomsen WC; Hubbard MA; Thomas CY
Mol Cancer Ther; 2011 Nov; 10(11):2124-34. PubMed ID: 21878657
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1.
Fang Y; Elahi A; Denley RC; Rao PH; Brennan MF; Jhanwar SC
Anticancer Res; 2009 Apr; 29(4):1255-62. PubMed ID: 19414372
[TBL] [Abstract][Full Text] [Related]
17. Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations.
Kaplan HG; Rostad S; Ross JS; Ali SM; Millis SZ
J Natl Compr Canc Netw; 2018 Aug; 16(8):967-974. PubMed ID: 30099373
[No Abstract] [Full Text] [Related]
18. Targeting of AKT/ERK/CTNNB1 by DAW22 as a potential therapeutic compound for malignant peripheral nerve sheath tumor.
Li XX; Zhang SJ; Chiu AP; Lo LH; Huang J; Rowlands DK; Wang J; Keng VW
Cancer Med; 2018 Sep; 7(9):4791-4800. PubMed ID: 30112810
[TBL] [Abstract][Full Text] [Related]
19. PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor.
Perrone F; Da Riva L; Orsenigo M; Losa M; Jocollè G; Millefanti C; Pastore E; Gronchi A; Pierotti MA; Pilotti S
Neuro Oncol; 2009 Dec; 11(6):725-36. PubMed ID: 19246520
[TBL] [Abstract][Full Text] [Related]
20. CircRNA hsa_circ_0002577 accelerates endometrial cancer progression through activating IGF1R/PI3K/Akt pathway.
Wang Y; Yin L; Sun X
J Exp Clin Cancer Res; 2020 Aug; 39(1):169. PubMed ID: 32847606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
